At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
150M PLX-PAD +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Intramuscular Injections of Allogeneic PLX-PAD Cells for the Regeneration of Injured Gluteal Musculature After Total Hip Arthroplasty
In Brief
A Phase 2 clinical trial evaluating 150M PLX-PAD, 300M PLX-PAD, and 1 other intervention for Total Hip Arthroplasty and Muscle Injury. Completed, enrolled 20 participants across 1 site.
Detailed Summary
Local administration of PLX-PAD single dose, intra-muscular injection for the regeneration of injured gluteal musculature after Total Hip Arthroplasty (THA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTotal Hip Arthroplasty, Muscle Injury
CountriesGermany
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2012
Enrollment StartNov 2012
Primary CompletionDec 2013
Study CompletionJun 2015
TodayJul 2026
First PostedFeb 3, 2012
Enrollment StartNov 1, 2012
Primary CompletionDec 1, 2013
Study CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 14.4 years ago
Interventions
150M PLX-PADbiological
Single course, multiple IM injections
300M PLX-PADbiological
Single course, multiple IM injections
Placebobiological
Single course, multiple IM injections